Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study
| Autor: | J. Rigal, J. Ciron, D. Biotti, Z. Lépine |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Multiple Sclerosis Neutropenia Asymptomatic Gastroenterology Internal medicine medicine Humans Prospective Studies Prospective cohort study Autoantibodies medicine.diagnostic_test business.industry Multiple sclerosis Neuromyelitis Optica Complete blood count medicine.disease Neurology Absolute neutrophil count Ocrelizumab Rituximab Myelin-Oligodendrocyte Glycoprotein Neurology (clinical) medicine.symptom business medicine.drug |
| Zdroj: | Revue neurologique. 178(3) |
| ISSN: | 0035-3787 |
| Popis: | Late-onset neutropenia (LON) after anti-CD20 therapy is a poorly described side effect in inflammatory disorders of the CNS. In this prospective study, patients treated with Rituximab or Ocrelizumab for MS, neuromyelitis optica spectrum disorders or MOG antibody-associated disease (MOGAD) were asked to perform complete blood count (CBC) every two weeks for six months, with the aim of identifying LON. Out of 152 patients, two (1,32%) had an absolute neutrophil count |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect